35623-11-1

Basic information

• Product Name: 3-[(Methylamino)sulphonyl]benzoic acid
• Synonyms: 3-[(Methylamino)sulphonyl]benzoic acid;3-[(METHYLAMINO)SULFONYL]BENZOIC ACID;3-[(methylamino)sulfonyl]benzenecarboxylic acid;3-(N-MethylsulfaMoyl)benzoic acid;3-(Methylsulphamoyl)benzoic acid;3-[(Methylamino)sulphonyl]benzoic acid, 3-Carboxy-N-methylbenzenesulphonamide;Benzoic acid,3-[(MethylaMino)sulfonyl]-;NSC 74787
• CAS NO: 35623-11-1
• Molecular Formula: C₈H₉NO₄S
• Molecular Weight: 215.23
• Product Categories: Acids and Derivatives;Boron, Nitrile, Thio,& TM-Cpds;API intermediates
• Mol File: 35623-11-1.mol
• Article Data: 14

Chemical Properties

• Melting Point: 211-213°C
• Boiling Point: 428.2 °C at 760 mmHg
• Flash Point: 212.7 °C
• Appearance: /
• Density: 1.41 g/cm³
• Vapor Pressure: 4.3E-08mmHg at 25°C
• Refractive Index: 1.57
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-[(Methylamino)sulphonyl]benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(Methylamino)sulphonyl]benzoic acid(35623-11-1)
• EPA Substance Registry System: 3-[(Methylamino)sulphonyl]benzoic acid(35623-11-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 35623-11-1(Hazardous Substances Data)

Usage

General Description

3-[(Methylamino)sulphonyl]benzoic acid, also known as Mefenamic acid, is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve mild to moderate pain. It works by reducing the production of prostaglandins, which are substances in the body that cause pain and inflammation. Mefenamic acid is commonly used to treat menstrual pain, as well as other types of pain such as headache, dental pain, and muscle pain. It can also be used to reduce fever. However, it is important to use this medication as directed by a doctor, as it may cause side effects and interact with other medications.

InChI:InChI=1/C8H9NO4S/c1-9-14(12,13)7-4-2-3-6(5-7)8(10)11/h2-5,9H,1H3,(H,10,11)

Upstream product

• 65-85-0 benzoic acid 
• 4025-64-3 3-Carboxybenzenesulfonyl chloride 
• 74-89-5 methylamine 

Downstream Products

• 1421507-30-3 (Z)-3-(4,5-difluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-N-methyl-benzene-sulphonamide 
• 1421506-93-5 (E)-3-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-N-methyl-benzene-sulphonamide 
• 1421506-44-6 (E)-3-(5-chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-N-methyl-benzenesulphonamide 
• 1421506-04-8 (E)-3-(6-chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-N-methyl benzenesulfonamide 
• 132390-65-9 3-formyl-N-methyl-benzenesulfonamide 
• 620600-73-9 3-(hydroxymethyl)-N-methylbenzene-1-sulfonamide 
• 35623-12-2 3-(hydrazinecarbonyl)-N-methylbenzenesulfonamide 
• 1423715-30-3 (E)-3-(2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazinecarbonyl)-N-methylbenzenesulfonamide 
• 1094752-93-8 methyl 3-(N-methylsulfamoyl)benzoate 
• 1018070-32-0 3-[(N-nitroso-methylamino)sulfonyl]-benzoic acid 
• 128950-21-0 4-<(N-methylamino)sulfonyl>benzoyl chloride 

Relevant articles and documents

Design and synthesis of newer N-benzimidazol-2yl benzamide analogues as allosteric activators of human glucokinase

Allosteric activators of human glucokinase (GK) had revealed significant hypoglycemic effects for therapy of type-2 diabetes (T2D) in animal as well as human models. Some newer N-benzimidazol-2yl substituted benzamide analogues were prepared and assessed for activation of GK accompanied by molecular docking investigations for predicting the bonding interactions of these derivatives with the residues in allosteric site of GK protein. Amongst the derivatives synthesized, compounds 2 and 7 strongly increased catalytic action of GK (GK activation fold >2.0 in comparison to control) in vitro. The results of in-vitro testing were supported by the molecular docking investigations of these analogues with GK protein’s allosteric site residues (showed appreciable H-bond interactions with Arg63 residue of GK). Derivatives investigated in present study afforded few lead compounds for the discovery of harmless and strong allosteric GK activating compounds for treating T2D.

BACE-2 INHIBITORY COMPOUNDS AND RELATED METHODS OF USE

Provided herein are novel compounds of Formulae I-III, and methods of using the same to selectively inhibit BACE2.

Synthesis and biological evaluation of novel (E)-N′-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors

Lysine specific demethylase 1 (LSD1) plays an important role in regulating histone lysine methylation at residues K4 and K9 on histone H3 and is recognized as an attractive therapeutic target in multiple malignancies. In this study, a series of novel (E)-N′-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides were synthesized and biologically evaluated for their potential LSD1 inhibitory effect. Among them, compounds 5a and 5n showed the most potent LSD1 inhibitory activity with IC50values of 1.4 and 1.7?nM, respectively, which were about 10 times more potent compared with (E)-N-(1-(5-chloro-2-hydroxyphenyl) ethylidene)-3-(morpholinosulf-only) benzohydrazide (J. Med. Chem. 2013, 56, 9496–9508; as reference compound). Compounds 5a and 5n also exhibited marked anti-proliferation activities against cancer cell lines that highly expressed LSD1. These results suggest that these optimized compounds might be served as promising LSD1 inhibitors against cancer, which merit further study.